BKM120 in Cancers With PIK3CA Activating Mutations

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Lung CancerBreast CancerColorectal CancerCholangiocarcinomaSolid Tumors
Interventions
DRUG

BKM120

100 MG PO QD in cycles of 28 days

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Massachusetts General Hospital

OTHER